Introduction
One of the major challenges encountered in gene therapy is appropriate spatial and temporal control of the expression of the therapeutic gene. This is especially true in the numerous cancer gene therapy regimens where extratumoral expression of the transgene can result in the destruction of normal tissue and lead to undesirable toxicity. Tissue specific promoters have been used to restrict the expression of a therapeutic gene to specific tissues or cell types. [1] [2] [3] [4] [5] [6] However, tissue restricted promoters are often active in both normal and neoplastic tissues. For a single injection of either virus resulted in equivalent tumor regression and survival upon ganciclovir treatment. In animals injected intratumorally with the CMVp/TK adenovirus, expression of the thymidine kinase gene was detected in tumors, as well as in liver samples. Expression of the suicide gene in combination with ganciclovir resulted in severe liver histopathology and in an elevation of hepatic enzymes. In sharp contrast, when the hTERT promoter controlled the thymidine kinase gene, transgene expression was observed in tumors, but not in liver samples. Normal liver function in these animals was confirmed by serum levels of hepatic enzymes that were indistinguishable from those of control healthy mice. These results indicate that by restricting thymidine kinase expression to tumor cells, the hTERT promoter allows the tumoricidal effect of the suicidal gene to be exerted without detrimental consequences on healthy tissues and vital organs. The tight specificity of expression imparted by the hTERT promoter will assist the development of novel approaches to the treatment of a broad array of cancer types. Gene Therapy (2001) 8, 568-578.
cancer therapeutics, promoters operative exclusively in transformed cells are desired. However, truly tumor specific promoters are rare and often useful only for treatment of the particular type of cancer cells from which they are derived. In contrast, the promoter of the telomerase reverse transcriptase gene controls selective expression of telomerase in over 85% of human malignancies, but is silent in most adult somatic tissues.
Telomerase is an enzyme involved in the synthesis and maintenance of chromosome termini known as telomeres that conventional polymerases are unable to replicate fully. The enzyme is a ribonucleoprotein particle whose RNA basepairs with telomere repeat sequences and serves as a template in the synthesis of new telomeres. The catalytic activity is provided by a large protein identified as hTERT (human telomerase reverse transcriptase) that shares homologies with viral reverse transcriptases but also contains distinct motifs conserved in all telomerase complexes identified to date. [7] [8] [9] Telomerase is present in germ cells but its activity is extinguished during early embryonic development 10, 11 and differentiation [12] [13] [14] and, consequently, is absent from most adult tissues. Limited telomerase activity is observed in some progenitor cells 15 of hematopoietic, 16, 17 epithelial, 18, 19 and gut origin, [20] [21] [22] as well as in mitotically active segments of hair follicles. 23 A hallmark of somatic cells grown in culture is their limited replicative capacity, 24 a phenomenon directly linked to the absence of telomerase and the ensuing gradual telomere attrition. 25, 26 In contrast, telomerase is reactivated in virtually all types of human malignancies and is readily detected in the most prevalent types of cancers such as breast, lung, prostate, pancreatic, colon, and ovarian cancers. 27, 28 Reactivation of telomerase is essential for telomere homeostasis and allows most tumor cells to escape normal replicative senescence characterized by the cessation of cellular division. RT-PCR analysis showed that the RNA component of telomerase is ubiquitously expressed in most somatic cells with only moderate up-regulation in human tumors, 29 whereas hTERT mRNA levels are virtually undetectable in the majority of normal somatic tissues. 7 As the RNA and catalytic components of telomerase are sufficient to reconstitute telomerase activity in vitro, 30 transcription initiation at the hTERT promoter appears to be the limiting step in the production of active telomerase, a finding that was further substantiated by recent run-off experiments. 31 We have analyzed genomic sequences directly upstream of the hTERT gene and showed that short promoter fragments of only approximately 100-200 base pairs can confer specific expression of heterologous genes to cells that normally express telomerase. We have shown that activity of the herpes simplex virus thymidine kinase gene expressed under the control of the hTERT promoter was restricted to tumor cells. Subsequent ganciclovir (GCV) administration resulted in the eradication of tumor cells in vitro and in animal models while leaving transfected normal somatic cells unaffected. An adenovirus engineered with an hTERT promoter fragment driving the thymidine kinase gene was capable of efficiently delivering the suicide gene to human tumors implanted in nude mice and elicited significant tumor regression upon GCV treatment. Tumor regression and survival of animals treated with the hTERT promoter vectors was equivalent to those observed using vectors carrying the cytomegalovirus (CMV) immediate-early gene promoter. However, the specificity of expression imparted by the hTERT promoter prevented the severe liver toxicity encountered with the use of constitutively active viral promoters, improving the potential safety of such gene therapeutics.
Results
Characterization of hTERT promoter fragments Genomic fragments immediately upstream of the hTERT coding sequences were cloned in front of a reporter gene encoding a secreted form of alkaline phosphatase and tested for their ability to drive expression of the reporter gene in several cell lines. Three promoter fragments were generated that comprise 2447, 204 and 82 basepairs of sequences upstream of the hTERT initiation codon. These constructs were introduced into several immortal, tumor or normal primary cell lines and the activity of the reporter gene was monitored by chemiluminescence. The results are shown in Figure 1 and represent an average of three separate experiments done in triplicate and standardized with a ␤-galactosidase control for transfection efficiency. In transient transfection experiments, all three promoter constructs showed activity in telomerase positive immortal lines (HeLa and 293 cells) but were completely silent in telomerase negative somatic cells such as human umbilical vein endothelial cells (HUVEC), foreskin fibroblasts (BJ) and retinal pigmented epithelial (RPE) cells. These experiments delineate a core promoter fragment comprising only 82 nucleotides of sequences adjacent to the hTERT initiator codon that is sufficient for promoter activity in immortal telomerase positive lines. When the promoter size was increased to 204 or 2447 nucleotide, activity of the reporter gene was reduced approximately two-to three-fold, suggestive of upstream repressor binding sites in the longer genomic fragments.
The hTERT promoter-driven thymidine kinase gene confers GCV sensitivity to tumor cells but does not affect normal somatic cells Herpes simplex virus thymidine kinase, unlike its mammalian homologues, efficiently converts the innocuous nucleoside analog, GCV, into a phosphorylated form that interferes with normal DNA replication and other cellular functions. 32 Our approach was to subordinate the thymidine kinase gene to the control of the hTERT promoter to sensitize tumor cells, but not somatic cells, to GCV treatment. Plasmids carrying the thymidine kinase gene under the control of the three different promoter fragments (pGRN266, pGRN267 and pGRN268, see Materials and methods) were transfected into several tumor and immortal cells, as well as into normal primary lines. Geneticin-resistant clones and mass populations were isolated and expression of the thymidine kinase gene was compared with the levels of expression of the endogeneous hTERT gene (Figure 2a ). For comparison, RT-PCR results on GAPDH message was also shown for each of these cell types (Figure 2a ). RT-PCR analyses revealed elevated expression of the thymidine kinase gene in immortal telomerase positive cells (143B, HT1080 and 293 cells) and little or no expression in any of the normal, telomerase negative cells (BJ, RPE and WI38). These results were consistent with the normal expression pattern of the endogenous hTERT gene. Representative clonal and mass populations of the osteosarcoma 143B line for each promoter construct were subjected to GCV treatment. Each of the three promoter fragments was able to drive sufficient expression of the thymidine kinase gene to eradicate 143B cells after 5-7 days of drug treatment (Figure 2b ). No significant difference in the annihilation of the cultures was observed between the three promoter fragments (see Discussion) and the 204 basepair promoter was used in all subsequent experiments, unless otherwise noted. These results were extended to several other tumor lines and the hTERTp/TK construct conferred GCV sensitivity to all tumor and immortal cell lines tested (Figure 2c ). In sharp contrast, normal cells, regardless of fibroblastic, epithelial, or endothelial origin, remained largely unaffected by the same treatment (Figure 2d ).
Bystander effect in vivo
To extend these results into animal models, both clonal and mass populations of 143B cells stably transfected , see Materials and methods) were injected into nude mice. Mice bearing 10-day-old tumors were subsequently injected with GCV or a control saline solution for a period of 10 days. Complete tumor regression was observed in all GCV-treated mice bearing hTERTp/TK-positive 143B tumors ( Figure 3 and data not shown). A significant difference in tumor growth was observed between GCVand saline-treated animals, which were implanted with the TK-positive 143B cells (P Ͻ 0.01, Figure 3 ). As expected, no tumor growth retardation was observed in GCV-or saline-treated animals implanted with the parental 143B cell line. Tumor regression observed in thymidine kinase suicide gene therapy is partially mediated by a bystander effect. 33 To determine if such a mechanism is operative in our model, mice were implanted with a mixture of cells that contained 20% of hTERTp/TK-positive 143B and 80% of unmodified 143B cells. Tumor regression data revealed the existence of a strong bystander effect when only 20% of hTERTp/TK-positive cells were used ( Figure 3 ). For reasons that are not clear, saline-treated tumors developed from hTERTp/TK-positive 143B cells showed slower growth in comparison to the other two control groups (100% 143BP + GCV and 100% 143BP + saline) of tumors. These differences however, were not statistically significant. These results demonstrate the accretive nature of the bystander effect to the initial destruction of hTERTp/TK-positive cells resulting from GCV treatment. In this experiment, between nine and 12 animals were used per group.
An adenoviral vector carrying the hTERTp/TK cassette retains the tumor-specific expression imparted by the hTERT promoter To assess the utility of the hTERT promoter in a suicide gene therapy further, an adenovirus vector carrying the hTERTp/TK cassette was constructed and amplified, yielding 2 × 10 13 density gradient purified viral particles. A second adenovirus (IntroGene, Leiden, The Netherlands) carrying the thymidine kinase gene under the control of the cytomegalovirus promoter (CMVp/TK) was similarly amplified and used as a positive control in our experiments. Specificity of the hTERT promoter in the adenovirus context was re-examined in 143B tumor cells and normal BJ fibroblasts. At an MOI (multiplicity of infection) of 100, both hTERTp/TK and CMVp/TK adenoviruses were cytotoxic to 143B cells in the presence of GCV (Figure 4 ). On the other hand, the hTERTp/TK adenovirus had a marginal effect, if any, on normal BJ fibroblasts, whereas the CMVp/TK adenovirus indiscriminately eradicated both tumor and normal cells ( Figure 4 ). GCV treatment in the absence of these viruses did not have any effect on the viability of either of these cell types and cells infected by either virus showed no evidence of death when GCV treatment was omitted (data not shown).
Effect of intratumoral administration of hTERTp/TK adenovirus and GCV treatment in vivo
Nude mice bearing 10-12-day-old native 143B tumors were injected with 9.6 × 10 8 p.f.u. (plaque forming units) of hTERTp/TK adenovirus followed by 10 days of GCV treatment. For comparison purposes, a separate group of 143B tumor bearing mice was injected with an identical dose of the CMVp/TK adenovirus. In two independent sets of experiments, similar tumor growth inhibition was observed in mice receiving either hTERTp/TK or CMVp/TK adenovirus in combination with GCV treatment (Figures 5a and b) . Mice receiving CMVp/TK adenovirus that were subsequently treated with GCV appeared to be more sick compared with the hTERTp/TK and GCV-treated animals. Providing gel food as the source of nutrients alleviated distress and prevented weight loss to Ͻ20%. Occasionally, a few mice in the CMVp/TK treated group appeared jaundiced, probably as a consequence of liver toxicity (see below). There was no statistically significant difference in the final tumor volumes of the hTERTp/TK or CMVp/TK adenovirus cohorts (P = 0.21 for Figure 5a and P = 0.18 for Figure 5b , respectively). However, both adenoviral constructs produced a significant difference in tumor volume when the GCV-treated animals were compared with the corresponding saline-treated mice (P Ͻ 0.005 and P Ͻ 0.001 for hTERTp/TK adenovirus and P Ͻ 0.02 and P Ͻ 0.001 for CMVp/TK adenovirus, Figure 5a and b, respectively). Most of the saline-treated animals in both groups were killed due to excessive tumor volume by day 42. In contrast, all mice receiving either the hTERTp/TK or CMVp/TK adenovirus survived until this time-point with significantly lower tumor burden. As expected, 143B tumor bearing mice receiving GCV treatment only (tumors injected with vehicle buffer) did not show any delay in tumor growth (Figure 5b ). For the data presented in Figure 5a , 21 mice were used for each of the GCV groups while the saline groups were comprised of 14 animals each. For the data presented in Figure 5b , hTERTp/TK + GCV and CMVp/TK + GCV groups consisted of eight and nine mice, respectively, while the buffer group had four mice.
We then determined if intratumoral delivery of hTERTp/TK and CMVp/TK adenoviruses followed by GCV treatment had any effect on the survival of tumorbearing mice ( Figure 6 ). In this experiment, control mice (a total of six) receiving an intratumoral buffer injection followed by GCV treatment were killed due to excessive tumor volumes (Ͼ1000 mm 3 ) and no animal survived past 62 days. In contrast, all 11 animals in the hTERTp/TK adenovirus and GCV-treated group survived during this same time period. Only one of 10 mice in the CMVp/TK adenovirus group was killed on day 62 due to high tumor burden. The experiment was terminated on day 62 when all mice were killed in the control group.
The hTERT promoter prevents the severe liver histopathology observed upon constitutive expression from the CMV promoter Tumor samples from mice injected with both adenoviruses were prepared throughout the course of the treatment and thymidine kinase mRNA levels were determined by RT-PCR analysis. Thymidine kinase expression was detected in all tumor samples and, in general, showed a slow decline over time (Figure 7a , left panel).As expected, the CMV promoter supported higher levels of thymidine kinase expression than the hTERT promoter in the tumors. In liver samples, thymidine kinase mRNA levels could be readily detected when transcribed from the CMV promoter (Figure 7a , right panel) and in some animals persisted for up to 30 days (data not shown). In sharp contrast, little or no thymidine kinase expression could be detected in liver samples obtained from mice injected with the hTERTp/TK adenovirus ( Figure 7a, right panel) .
In order to assess any therapeutic benefit of the restricted thymidine kinase expression imparted by the hTERT promoter, blood samples from three mice in each of the treatment groups were analyzed for circulating liver enzymes (alkaline phosphatase, AP; alanine aminotransferase, ALT; and aspartate aminotransferase, AST).
Gene Therapy Figure 7b shows that mice injected with the CMVp/TK adenovirus and treated with GCV had high levels of all three liver enzymes compared with control animals (P Ͻ 0.01 for all three enzymes). More importantly, the levels of hepatic enzymes in mice treated with the hTERTp/TK adenovirus and GCV or in the saline-treated control groups were indistinguishable from those measured in healthy animals. In addition, histological analysis of liver tissue sections (Figure 7c) showed a severe pathology in mice treated with the CMVp/TK adenovirus and GCV, as measured by individual cell necrosis and/or degeneration, along with a marked hepatocellular hypertrophy. No abnormalities were observed in liver samples from mice that underwent hTERTp/TK adenovirus injection and GCV administration. From these results, it appears that the toxicity observed in the liver tissues is the result of high, unregulated levels of thymidine kinase expression from the CMV promoter. The hTERTp/TK adenovirus, on the other hand, is able to destroy tumor cells efficiently by moderate expression of the thymidine kinase gene, while ensuring a virtually complete absence of expression in liver tissue that prevents GCV-associated toxicity.
Discussion
Telomerase activity is elevated in the vast majority of human tumors as a result of an increased rate of transcription initiation of the hTERT gene encoding the catalytic subunit of the enzyme. 31 The hTERT promoter lies in a large CpG island and a role for DNA methylation in the regulation of telomerase activity has been suggested, although no generalized methylation pattern could be correlated with the expression of the hTERT gene. 34 The exact mechanisms governing the differential transcription activity of the hTERT gene in tumor and normal somatic cells are not well characterized. However, multiple control elements can be found throughout the promoter region and may lead to the characterization of the factors involved. For instance, estrogen, 35, 36 c-Myc 37-42 and Sp1 43 have been found to activate transcription of the hTERT gene, whereas p53, 44 WT-1 45 and Mad1 31 down-regulate its transcription. Of particular interest, is the finding that the differential activities of the hTERT promoter in normal and tumor lines could be attributed to the abundance of the c-Myc oncoprotein. 42 However, one of the promoter constructs we used in our studies lacks both proximal and distal binding site for c-Myc, but remained capable of promoting efficient transcription of the thymidine kinase or reporter gene in tumor cells. The plethora of potential binding sites for transcription factors found on the hTERT promoter suggests that telomerase activity can be controlled by a variety of mechanisms and is likely to be differentially regulated depending on the cellular context or in response to specific stimuli.
Our results establish that the cloned hTERT promoter fragments drive transgene expression with the same specificity as the endogenous telomerase promoter. The cloned hTERT promoters were active in each of the tumor and immortal cell lines tested while no hTERT promoter activity was detected in the normal tissues from which these cell lines were derived. Introduction of the thymidine kinase gene under the control of the hTERT promoter into normal and immortal cells resulted in a pattern of transgene expression that paralleled endogenous hTERT activity. Previously characterized tissue-specific promoters 4 are generally active only in the type of cancer from which they are derived or, at best, in a very limited number of tumor types. 6, 47, 48 In contrast, the hTERT promoter is active in cancers from very different etiology which augurs well for applications of an hTERT promoter gene therapy in a wide range of human malignancies.
The adenovirus carrying the thymidine kinase gene under the control of the hTERT promoter proved to Figure 2 
(a) Expression of the thymidine kinase gene subordinated to the hTERT promoter. Expression of the thymidine kinase gene was measured by RT-PCR in tumor lines (143B, HT1080 and 293, right panel) and in normal somatic cells (BJ, RPE and WI38, right panel). Expression levels of the endogenous hTERT gene in 293 and BJ cells are shown for comparison (left panel). (b) The hTERT promoter strength is sufficient to effectively mediate tumor cell destruction. Plasmid pGRN265, pGRN266 or pGRN267 was transfected into 143B cells and G418-resistent clones were subjected to GCV treatment (30 m final concentration; bottom panel) or were mock-treated (top panel). Untransfected 143B cells served as control. All three promoter configurations were capable of driving sufficient expression of the thymidine kinase gene to eradicate the cell cultures over a period of 5-7 days after drug treatment. (c) The hTERTp/TK cassette confers GCV sensitivity to all tumor cells tested. The hTERTp/TK cassette was transfected into several tumor lines (upper panels) and G418-resistent clones or mass populations were subjected to GCV treatment. Complete cell death was observed for all lines after 5-7 days of drug administration (lower panels). (d) The hTERTp/TK cassette does not affect normal somatic cells. The hTERTp/TK cassette was transfected into several normal cell lines (upper panel) and G418-resistent clones or mass populations were subjected to GCV treatment. No significant detrimental effect was observed in these cells after drug treatment (lower panels) in comparison to the control cultures (upper panels).

Figure 3 Bystander effect observed in nude mice bearing hTERTp/TKpositive 143B tumors. Balb/c nude mice were injected with a mixture of hTERTp/TK-positive and parental 143B cells at a ratio of 20:80 (2 × 10 5 cells per mouse). Eleven days later, when the tumors were palpable, GCV or saline was administered to these animals for a period of 10 days. Mice injected exclusively with parental 143B cells, or hTERTp/TK-positive 143B cells, were used as negative and positive controls, respectively. Tumor volume data from the two corresponding saline-treated groups of animals are also presented. Between 9 and 12 animals were used per group.
inhibit tumor growth efficiently. In general, it is expected that only a fraction of tumor cells become infected after local injection of conventional replication-deficient adenoviral vectors. Our in vitro and in vivo studies indicate that even with the telomerase promoter, the thymidine kinase bystander effect remains operative and is likely to contribute significantly to tumor cell destruction.
The hTERT promoter drives transcription of approximately 5-10 copies of mRNA in tumor cells and the hTERT protein has been measured at similar concentrations (N Kim and J Trager, personal communication). These extremely low levels of transcription are likely to influence the choice of the transgene in a clinical setting. However, using the thymidine kinase gene, we did not observe significant differences in the in vitro or in vivo efficacy of tumor cell destruction when the stronger CMV Gene Therapy
Figure 4 hTERTp/TK adenovirus and GCV mediated killing in vitro is restricted to tumor cells. In addition to hTERTp/TK adenovirus, an adenovirus carrying the thymidine kinase gene under the control of the CMV promoter (IntroGen) was used as control to infect 143B and BJ cells. Cells were seeded in six-well plates at a density of 5 × 10 5 cells per well. After overnight culture, the cells were infected with the hTERTp/TK or the CMVp/TK adenovirus vector at an MOI of 100 (or were mock-infected) for a period of 3 h followed by the addition of complete medium containing 30 m GCV. The GCV treatment was continued for a period of 4 days. Both the hTERTp/TK and the CMVp/TK adenoviruses proved to be comparably efficient in eradicating tumor cells (lower two panels, right). However, the CMVp/TK adenovirus also mediated complete destruction of normal BJ cells (top right) whereas the hTERTp/TK adenovirus left BJ cells largely unaffected (second from the panel, right).
immediate-early gene promoter was used to drive suicide gene expression. These results suggest that the hTERT promoter is capable of producing and maintaining a threshold level of thymidine kinase protein sufficient to eradicate tumor cells and that higher expression of the suicide gene may not result in additional therapeutic efficacy. 49, 50 The strict specificity of cellular activation displayed by the hTERT promoter indicates that more potent or more toxic transgenes could be used.
Tumors regrew in some of the animals used in this study, regardless of the promoter used in the adenovirus vector. While it is difficult to measure precisely the amount of thymidine kinase in tumors after GCV treatment, in vitro data indicate that cells reappearing after drug treatment did not express the thymidine kinase gene. Re-infection of these cells with the hTERTp/TK adenovirus resulted in the complete eradication of the cell population (data not shown). Therefore inefficient vector delivery to tumors and/or down-regulation of thymidine kinase gene expression are likely to be the cause of our inability to eradicate tumors in these animals completely. Future studies with more potent suicide genes could limit tumor re-growth. In the animal studies, little or no expression of the thymidine kinase gene was observed in liver samples using the hTERTp/TK adenovirus. In contrast, use of the CMV promoter in the same context drove high liver expression of the suicide gene. Expression of the thymidine kinase gene from the CMV promoter led to significant liver toxicity upon GCV administration whereas the hTERTp/TK virus preserved a normal liver phenotype. These results indicate that expression cassettes can influence the efficacy and safety of gene therapy and that the hTERT promoter can be used to reduce extratumoral expression of the transgene efficiently.
Despite its absence in most adult tissues, telomerase activity has been detected in germ cells as well as in some progenitor and lymphoid cells. The presence of telomerase may indicate potential expression of transgenes when the hTERT promoter is utilized in these cells. However, in most progenitor and lymphoid cells, telomerase expression is a transient response to proliferative stimuli. Selection of a delivery vector with limited tropism, such as adenovirus, may limit transduction of these specific cell types and prevent any effects of hTERT promoter mediated transgene expression.
In this study, we demonstrated the usefulness of the hTERT promoter in restricting the expression of a suicide gene to tumor cells. Our results suggest that the use of the hTERT promoter in therapeutic regimens involving genetic eradication of malignancies can preserve the integrity of healthy tissues and should mitigate some of the associated toxicity. The broad activity of the hTERT promoter in most tumor tissues indicates that this approach has the potential to be used in virtually all types of cancers.
Materials and methods
Construction of the hTERT promoter vectors
Construction of the hTERTp/SEAP vectors has been reported elsewhere. 31, 38 with the exception of pGRN175. Briefly, pGRN150, pGRN176 and pGRN175 carry the SEAP gene under the control of 2447, 204 and 82 base pairs of hTERT promoter sequences, respectively. The control vectors are described on the manufacturer's web site (http://www.clontech.com). pGRN266, pGRN267 and pGRN268 were constructed in three steps. First, each of the three hTERTp/SEAP cassette was transferred into SalI/NotI-digested pEGFP-1 (Clontech, Palo Alto, CA, USA) in order to provide a selectable marker (neo r ). Next, the EcoRI site in each of the newly created vectors was deleted to allow replacement of the SEAP gene. Finally, the thymidine kinase gene was amplified by PCR from plasmid pKS-TK (kind gift of HW Lee and RA DePinho, Dana Farber Cancer Institute, Boston, MA, USA) using TK-F (GCAGAATTCCACAGGCTTGG TACCCCTGCCAT) and TK-R (GCAATCTAGAGGC CGGCCTCAGTTAGCCTCCCCCATCTC) and ligated into the EcoRI/FseI-digested plasmids obtained in the second step, yielding plasmids pGRN266 and pGRN267. For pGRN268, PCR was performed with a TK-R primer containing an XbaI site and the thymidine kinase fragment was ligated into the EcoRI/(unmethylated)XbaIdigested plasmid obtained in the second step. In pGRN266, pGRN267 and pGRN268, the thymidine kinase gene is driven by 2447, 204 and 82 base pairs of hTERT promoter sequences, respectively. The hTERTp/TK adenovirus was constructed by ligating the NotI/BamHI fragment of pGRN267 into the NotI/BamHI sites of the pQBI-AdBN (AdenoQuest) transfer vector (Quantum Biotechnology, Montreal, Canada). This vector is a first generation, replication-deficient, human serotype 5 adenovirus (Ad-5) lacking the E1 and E3 regions. The hTERTp/TK adenovirus was generated by homologous recombination in 293 cells followed by plaque purification. Adenoviral pre-stocks were then amplified in 293 cells and purified by a CsCl density gradient centrifugation. A second recombinant, E1-deleted, adenovirus carrying the TK gene under the control of cytomegalovirus immediate-early promoter and enhancer (CMVp/TK) was obtained from IntroGene as a pre-stock. The construction of the Ad-5-based CMVp/TK virus has been described elsewhere in detail. 51 CMVp/TK adenovirus was also amplified in 293 cells and subsequently purified through a CsCl density gradient.
Creation of stable cell lines Stable cell lines containing the plasmids pGRN266, pGRN267 and pGRN268 were established by electroporation of 10 6 cells with 5 g of plasmid DNA at 270 V for immortal lines and 5 × 10 6 cells with 20 g of plasmid DNA at 320 V for primary cell lines. Geneticin-resistant foci were isolated after 10-14 days and propagated under selection (200 g/ml geneticin). The following cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA) and grown as described below: 143B osteosarcoma cells, Aspc-1 pancreatic tumor cells, DAOY medulloblastoma cells, HT1080 fibrosarcoma cells, IMR-90 and WI-38 fibroblasts. The RPE cell line was obtained from Dr L Hjemeland of University of California, Davis, CA, USA while BJ fibroblasts were a kind gift from Dr J Smith of UTSW, Dallas, TX, USA. All cell lines were grown in complete DMEM medium, supplemented with 10% FCS, 2 mm glutamine and in some cases, with 100 U/ml penicillin/streptomycin (all materials obtained from Life Technologies, Grand Island, NY, USA).
RT-PCR analysis
Total RNA was isolated from cells using RNeasy Mini Kits (Qiagen, Santa Clara, CA, USA), while poly(A) + RNA was isolated using Oligotex mRNA Mini Kits (Qiagen). RT-PCR reactions were performed as follows: 1 g of total RNA or 200 ng of poly(A) + RNA and 80 ng of random hexamer oligonucleotides were combined and denatured at 95°C for 5 min. Buffer containing 10 mm DTT, 500 m dNTPs, and 100 U SuperScript II reverse transcriptase (GibcoBRL) was added to a 10 l reaction and first strand synthesis was performed according to manufacturer's instructions. PCR fragments were generated using 2.5 m primers to the thymidine kinase gene (forward: AGCAAGAAGCCACGGAAGTC and reverse: GGCGGTCGAA GATGAGGGTGA) in buffer containing 250 m dNTPs, 1 m MgCl 2 , 0.1 unit Taq polymerase (Promega, Madison, WI, USA), and 1/10th of the first strand reaction mixture. Cycling conditions were 94°C for 30 s, 65°C (−0.5°C/cycle) for 30 s, 72°C for 90 s over the first 10 cycles, followed by 94°C for 30 s, 60°C for 30 s, 72°C for 90 s over another 25 cycles. Fragments were visualized by agarose gel electrophoresis. RT-PCR method for the detection hTERT and GAPDH expression was performed as previously described. 7 GCV treatment in vitro hTERTp/TK-positive and parent cells were seeded separately in 24-well tissue culture dishes and treated with GCV (Cytovene-IV, Roche Laboratories, Nutley, NJ, USA) reconstituted in sterile phosphate buffered saline (PBS) solution. Cells were grown under selection according to ATCC recommendations and medium and GCV were changed every 3 days.
Adenoviral transduction in vitro
Cells were plated in six-well plates. hTERTp/TK or CMVp/TK adenovirus was applied to cells in 1 ml of media at various MOIs, 24 h later. Cells were incubated at 37°C for 3 h followed by addition of 2 ml media containing 30 m GCV (final concentration). Cell cultures were replenished every day with fresh medium containing GCV. 
Tumor implantation and GCV treatment
52
In vivo gene therapy using adenoviral vectors Ten-day-old subcutaneously grown 143B tumors were injected with 9.6 × 10 8 p.f.u. of hTERTp/TK or CMVp/TK adenoviruses. At this time, tumors were palpable and tumor volumes ranged between 35 and 50 mm 3 (see Figure legends for details) . Adenoviral vectors were injected in 10-30 l of 10 mm Tris-HCl (pH 8.0), 150 mm NaCl, 2 mm MgCl 2 and 5% sucrose (w/v) at three different sites in each tumor. Eighteen hours later, animals were treated intraperitoneally with 0.1 ml GCV or saline solution. To prevent weight loss and dehydration due to TK and GCV toxicity, mice were kept on Transgel food supplemented with nutrients and vitamins (Charles River, Wilmington, DE, USA) during the course of the GCV treatment. Animals were killed when tumor volume was у1000 mm 3 .
For survival studies, all animals were killed when tumor volumes in the control groups reached 1000 mm 3 and wet tumor weight was determined.
Liver histology and blood enzyme analysis Two days after the completion of GCV treatment, three mice from each group were killed and liver and blood samples were collected. For histology, 5 m paraffinembedded liver sections were stained with hematoxylineosin (HE) and examined by light microscopy. Liver function was analyzed by automated colorimetric assays of the following enzymes: alkaline phosphatase (AP), alanine aminotransferase (ALT) and aspartic aminotransferase (AST). Normal range for these enzymes in mouse blood is as follows: AP (45-222 U/l), ALT (22-77 U/l), AST (54-269 U/l).
Statistics
Tumor volume and liver enzyme data represent means ± s.d. For statistical analysis, unpaired two-tailed Student's t tests were used; P values Ͻ 0.05 were considered to be of statistical significance. A Kaplan-Meier plot was generated to present the survival data of tumor-bearing mice. Subsequently, the log rank test was used to determine statistical significance between each treatment group.
